FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

The Lancet Oncology
Chiara CremoliniAlfredo Falcone

Abstract

In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved progression-free survival of patients with metastatic colorectal cancer compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab. In this updated analysis, we aimed to provide mature results for overall survival-a secondary endpoint-and report treatment efficacy in RAS and BRAF molecular subgroups. TRIBE was an open-label, multicentre, phase 3 randomised study of patients (aged 18-70 years with Eastern Cooperative Oncology Group [ECOG] performance status of 2 or less and aged 71-75 years with an ECOG performance status of 0) with unresectable metastatic colorectal cancer who were recruited from 34 Italian oncology units. Patients were randomly assigned (1:1) via a web-based procedure to receive FOLFIRI plus bevacizumab or FOLFOXIRI plus bevacizumab. Bevacizumab was given as a 5 mg/kg intravenous dose. FOLFIRI consisted of a 180 mg/m(2) intravenous infusion of irinotecan for 60 min followed by a 200 mg/m(2) intravenous infusion of leucovorin for 120 min, a 400 mg/m(2) intravenous bolus of fluorouracil, and a 2400 mg/m(2) continuous infusion of fluorouracil for 46 h. FOLFOXIRI cons...Continue Reading

References

Sep 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patricia A TangLillian L Siu
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marc BuysePascal Piedbois
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan D RichmanPhilip Quirke
Dec 3, 2010·Journal of the National Cancer Institute·Gianluca MasiAlfredo Falcone
Nov 15, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Clemens GiessenVolker Heinemann
Sep 13, 2013·The New England Journal of Medicine·Jean-Yves DouillardScott D Patterson
Oct 22, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F LoupakisA Falcone
Sep 6, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemUNKNOWN ESMO Guidelines Working Group
Oct 23, 2014·The New England Journal of Medicine·Fotios LoupakisAlfredo Falcone
Dec 30, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T GruenbergerR Adam
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemFortunato Ciardiello

❮ Previous
Next ❯

Citations

Oct 1, 2015·Clinical Colorectal Cancer·Giuseppe AprileGianpiero Fasola
Feb 7, 2016·Critical Reviews in Oncology/hematology·Yu SunakawaHeinz-Josef Lenz
Dec 19, 2015·The Lancet Oncology·Ayumu MatsuokaYuichi Ando
Mar 15, 2016·Expert Opinion on Biological Therapy·Camille Sibertin-BlancJean-François Seitz
Feb 11, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C CremoliniA Falcone
Mar 25, 2016·Expert Review of Anticancer Therapy·Timothy J PriceJeremy D Shapiro
May 10, 2016·Expert Opinion on Pharmacotherapy·J J M Kwakman, C J A Punt
May 8, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Sartore-BianchiG W Prager
Jul 7, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemD Arnold
Jul 16, 2016·Annals of Surgical Oncology·Paul J Karanicolas, Yoo-Joung Ko
Dec 19, 2015·The Lancet Oncology·Fotios LoupakisAlfredo Falcone
Oct 17, 2016·Revue des maladies respiratoires·D Sefrioui, P Michel
Dec 7, 2016·Nature Reviews. Clinical Oncology·Cornelis J A PuntLouis Vermeulen
Feb 7, 2017·American Journal of Clinical Pathology·Antonia R SepulvedaJan A Nowak
Mar 10, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dominik Paul ModestVolker Heinemann
Apr 5, 2017·Expert Opinion on Biological Therapy·Debora BasileGiuseppe Aprile
May 12, 2017·Cancers·Patrick M Boland, Wen Wee Ma
Jun 27, 2017·Expert Opinion on Pharmacotherapy·Antonio RossiEvaristo Maiello
Jul 15, 2017·International Journal of Molecular Sciences·Alessia BignucoloGiuseppe Toffoli
Jul 15, 2017·Nature Reviews. Cancer·Michele De PalmaTatiana V Petrova
Jul 21, 2017·British Journal of Cancer·M A AllardJ Figueras
Feb 24, 2018·Expert Opinion on Biological Therapy·Gonzalo Tapia Rico, Timothy J Price
Oct 30, 2016·Tumori·Chiara Cremolini, Filippo Pietrantonio
Jan 13, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Dell'AquilaD Santini
Mar 1, 2018·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Takeshi TakamotoMasatoshi Makuuchi
Dec 6, 2017·Indian Journal of Surgical Oncology·Yuji MiyamotoHeinz-Josef Lenz
Sep 8, 2016·World Journal of Gastrointestinal Pharmacology and Therapeutics·Gabriel GlockzinPompiliu Piso
Jan 31, 2018·Acta Oncologica·Eelco de BreeIgnace H de Hingh
Aug 23, 2017·Future Oncology·Khalil SalehGeorges Chahine

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.